Cizzle Biotechnology (Cizzle), focused on cancer diagnostics, was spun out of the University of York to exploit the biomarker, variant CIZ1b, for early detection of different forms of lung cancer. There is high medical need for a simple blood test that allows early detection of lung cancer and potentially improve patient outcomes. Since listing, Cizzle has been considering how to develop a broader screening test that could be used to test for other cancers and developing a companion diagnostic for autoimmune disease. Cizzle continues to make progress, and has expanded the number of potential income streams through strategic partnerships
07 Dec 2021
News flow driven by deals
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
News flow driven by deals
Cizzle Biotechnology Holdings PLC (E7F0:FRA) | 0 0 0.0%
- Published:
07 Dec 2021 -
Author:
Martin Hall -
Pages:
8
Cizzle Biotechnology (Cizzle), focused on cancer diagnostics, was spun out of the University of York to exploit the biomarker, variant CIZ1b, for early detection of different forms of lung cancer. There is high medical need for a simple blood test that allows early detection of lung cancer and potentially improve patient outcomes. Since listing, Cizzle has been considering how to develop a broader screening test that could be used to test for other cancers and developing a companion diagnostic for autoimmune disease. Cizzle continues to make progress, and has expanded the number of potential income streams through strategic partnerships